

## UTILIZATION MANAGEMENT MEDICAL POLICY

**POLICY:** Ophthalmology – iDose TR Utilization Management Medical Policy

- iDose® TR (travoprost intracameral implant – Glaukos)

**REVIEW DATE:** 02/25/2026

---

### OVERVIEW

iDose TR, a prostaglandin analog, is indicated for the reduction of intraocular pressure (IOP) in **open-angle glaucoma** or **ocular hypertension**.<sup>1</sup>

### Disease Overview

Glaucoma, a disease that damages the eye's optic nerve, is the leading cause of blindness in people > 60 years of age.<sup>2</sup> Reduction of IOP, regardless of the pretreatment IOP, reduces the risk of disease progression.<sup>3</sup> In addition, IOP reduction may prevent the onset of early glaucoma in patients with ocular hypertension.

Ophthalmic prostaglandins (e.g., bimatoprost, latanoprost), beta-blockers (e.g., levobunolol, timolol), alpha-agonist (brimonidine), carbonic anhydrase inhibitors (brinzolamide, dorzolamide), rho kinase inhibitor (netarsudil), and fixed combination products are used to treat glaucoma.<sup>3</sup> The choice of product is influenced by potential cost, adverse event profile, dosing schedule, and the degree of pressure lowering needed.

### Dosing Considerations

iDose TR is a travoprost delivery system consisting of a travoprost releasing implant pre-loaded in a sterile, single-dose inserter.<sup>1</sup> Each implant contains 75 mcg travoprost. iDose TR is administered intracamerally through a small, clear corneal incision and is anchored into the sclera at the iridocorneal angle. It is not recommended to readminister an iDose TR implant more than once per year.

### POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of iDose TR. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indications. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for one implant per treated eye (i.e., one implant per treated eye; maximum of two implants per patient). Note that a 3-month (90 days) approval duration is applied to allow for the one-time treatment of one or both eye(s). Because of the specialized skills required for evaluation and diagnosis of patients treated with iDose TR as well as the monitoring required for adverse events and long-term efficacy, approval requires iDose TR to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

## RECOMMENDED AUTHORIZATION CRITERIA

Coverage of iDose TR is recommended in those who meet one of the following criteria:

### FDA-Approved Indications

---

**1. Ocular Hypertension.** Approve one implant per affected eye(s) if the patient meets ALL of the following (A, B, C, and D):

A) Patient is  $\geq 18$  years of age; AND

B) Patient meets BOTH of the following (i and ii):

i. Patient has tried at least two ophthalmic prostaglandins (either as monotherapy or as concomitant therapy) for the treatment of open-angle glaucoma or ocular hypertension; AND

Note: Examples of ophthalmic prostaglandins include bimatoprost 0.03% ophthalmic solution, latanoprost 0.005% ophthalmic solution, travoprost 0.004% ophthalmic solution; Lumigan (bimatoprost 0.01% ophthalmic solution), Vyzulta (latanoprostene bunod 0.024% ophthalmic solution), Xelpros (latanoprost 0.005% ophthalmic emulsion), tafluprost 0.0015% ophthalmic solution, Iyuzeh (latanoprost 0.005% ophthalmic solution), and Omlonti (omidenepag isopropyl 0.002% ophthalmic solution).

ii. Patient has tried at least two other ophthalmic products (either as monotherapy or as concomitant therapy) from two different pharmacological classes for the treatment of open-angle glaucoma or ocular hypertension; AND

Note: Examples of pharmacological classes of ophthalmic products for the treatment of open-angle glaucoma or ocular hypertension include beta-blockers, alpha-agonist (brimonidine), carbonic anhydrase inhibitors, and rho kinase inhibitor (netarsudil).

C) For each of the ophthalmic medications that was tried, the patient meets ONE of the following (i or ii):

i. According to the prescriber, patient has had inadequate efficacy to the previously tried ophthalmic products; OR

ii. According to the prescriber, patient has experienced adverse event(s) severe enough to warrant discontinuation of the previously tried ophthalmic products; AND

D) The medication is administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve up to one iDose TR implant per treated eye(s) [two implants per patient].

---

**2. Open-Angle Glaucoma.** Approve one implant per affected eye(s) if the patient meets ALL of the following (A, B, C, and D):

A) Patient is  $\geq 18$  years of age; AND

B) Patient meets BOTH of the following (i and ii):

i. Patient has tried at least two ophthalmic prostaglandins (either as monotherapy or as concomitant therapy) for the treatment of open-angle glaucoma or ocular hypertension; AND

Note: Examples of ophthalmic prostaglandins include bimatoprost 0.03% ophthalmic solution, latanoprost 0.005% ophthalmic solution, travoprost 0.004% ophthalmic solution; Lumigan (bimatoprost 0.01% ophthalmic solution), Vyzulta (latanoprostene bunod 0.024% ophthalmic solution), Xelpros (latanoprost 0.005% ophthalmic emulsion), tafluprost 0.0015% ophthalmic solution, Iyuzeh (latanoprost 0.005% ophthalmic solution), and Omlonti (omidenepag isopropyl 0.002% ophthalmic solution).

ii. Patient has tried at least two other ophthalmic products (either as monotherapy or as concomitant therapy) from two different pharmacological classes for the treatment of open-angle glaucoma or ocular hypertension; AND

Note: Examples of pharmacological classes of ophthalmic products for the treatment of open-angle glaucoma or ocular hypertension include beta-blockers, alpha-agonist (brimonidine), carbonic anhydrase inhibitors, and rho kinase inhibitor (netarsudil).

- C) For each of the ophthalmic medications that was tried, the patient meets ONE of the following (i or ii):
- i. According to the prescriber, patient has had inadequate efficacy to the previously tried ophthalmic products; OR
  - ii. According to the prescriber, patient has experienced adverse event(s) severe enough to warrant discontinuation of the previously tried ophthalmic products; AND
- D) The medication is administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve up to one iDose TR implant per treated eye(s) [two implants per patient].

---

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of iDose TR is not recommended in the following situations:

1. **Retreatment of Previously Treated Eye(s) Within the Past 1 Year.** It is not recommended to readminister iDose TR more than once per year.<sup>1</sup>
2. **Concurrent use of iDose TR with Durysta (bimatoprost intracameral implant).** Durysta is another intracameral prostaglandin analog implant and should not be used in combination with iDose TR.<sup>4</sup>
3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. iDose<sup>®</sup> TR intracameral implant [prescribing information]. San Clemente, CA: Glaukos; January 2026.
2. Goyal A. Understanding glaucoma: symptoms, causes, diagnosis, treatment. Available at: <https://www.aao.org/eye-health/diseases/what-is-glaucoma>. Published January 5, 2026. Accessed on February 19, 2026
3. Gedde SJ, Vinod K, Wright MW, et al. The American Academy of Ophthalmology. Primary Open-Angle Glaucoma Preferred Practice Pattern.<sup>®</sup> 2020 Available at: [https://www.aajournal.org/article/S0161-6420\(20\)31024-1/fulltext](https://www.aajournal.org/article/S0161-6420(20)31024-1/fulltext). Accessed on February 19, 2026.
4. Durysta<sup>®</sup> [prescribing information]. North Chicago, IL: AbbVie; October 2024.

**HISTORY**

Type of Revision	Summary of Changes	Review Date
New Policy		02/14/2024
Annual Revision	No criteria changes.	02/12/2025
Annual Revision	<p><b>Policy Statement:</b> Approval duration was changed from 1 month (30 days) to 3 months (90 days).</p> <p><b>Ocular Hypertension.</b> The statement “Approve for a one-time use in each treated eye (i.e., one implant per treated eye; a total of two implants per patient)” was changed to “Approve one implant per affected eye(s)”. The requirement that patient is not receiving retreatment of eyes previously treated with iDose TR was removed.</p> <p><b>Open-Angle Glaucoma.</b> The statement “Approve for a one-time use in each treated eye (i.e., one implant per treated eye; a total of two implants per patient)” was changed to “Approve one implant per affected eye(s)”. The requirement that patient is not receiving retreatment of eyes previously treated with iDose TR was removed.</p> <p><b>Conditions Not Recommended for Approval.</b> The condition “Retreatment of previously treated eye(s)” was revised to “Retreatment of previously treated eye(s) within the past 1 year”.</p>	02/25/2026